common side effects of glp-1 receptor agonists Your guide to Gastrointestinal Adverse Effects of GLP-1

The European Medicines Agency has issued a positive recommendation on the same indication

Tirzepatide was approved in 2022 as Mounjaro for diabetes, and in 2024 as Zepbound for obesity, with exclusivity running until May 2027

This move comes as these diabetes and weight-loss drugs see explosive demand in India, fueled by rising obesity rates and recent price reductions

and increased insulin early AUC and C-peptide total and early AUCs

This guide examines peer-reviewed research on EVOO and GLP-1 secretion, hydroxytyrosol and insulin sensitivity, oleocanthal and inflammation, and why these olive-specific compounds are distinct from other dietary polyphenols